Natural Intelligence Cancer Prevention Project
Rigvir group has made a decision to offer a fundamentally new
approach to cancer prevention, that would allow to identify high cancer-risks timely and address
them effectively, using the oncolytic virus Rigvir.
Henceforth, Rigvir virus is going to be developed also in the non-medical field which could
provide preventive help to people with high cancer-risks or scientifically proven cancer
presence in the body even before cancer can be diagnosed.
Promotional video
Natural Intelligence Cancer Prevention Project
Rigvir group has made a decision to offer a fundamentally new approach to cancer prevention.
Shooting Star
To honour and thank Aina Muceniece – a scientist, oncologist, immunologist and virologist, as well as Rigvir inventor and founder of practical cancer virotherapy for the possibility to live a full life, Harijs Zariņš – a musician and poet, has composed a song called “Shooting Star”.
Watch video
Shooting Star
To honour and thank Aina Muceniece – a scientist, oncologist, immunologist and virologist, as well as Rigvir inventor and founder of practical cancer virotherapy for the possibility to live a full life, Harijs Zariņš – a musician and poet, has composed a song called “Shooting Star”.
“Another Taste of Life” film premiere on television
The movie tells us about 8 inspirational people affected by cancer gathering from all around the world to attempt the Mont Blanc. Movie is freely available in several languages on: www.anothertasteoflife.com
Go to website
A unique chronicle of Rigvir's development has been created on Instagram
Anyone interested can learn about the history of Rigvir's development from the very beginning to the present day on the Instagram and continue to follow all the most important Rigvir related news.
Go to Instagram
Rigvir group has signed a license agreement
Agreement was signed on the development, registration and sales of Rigvir medicine in the CIS region countries.
Read More
We Believe in the Good Virus
We invest in biomanufacturing and we focus on growing our portfolio of virotherapy medicines that meet the real needs of patients.
Products
Publication of New Toxicity study
4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7
virus Rigvir
The results show that there were no significant test item-related adverse events.
Based on the results, the no-observed-adverse-effect level
(NOAEL) was considered to be the highest dose tested.
Rigvir Group is looking for partners globally
To finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.
For Investors
Rigvir Group finalised an ERAF funded project - GLP Toxicity Study of Rigvir
The aims of the project have been reached, and as a result a NOAEL (no adverse effect level) has been determined.
Read More
GMP compliance certificate received
Rigvir's new API (Active pharmaceutical ingredient) center of manufacturing has received GMP (Good Manufacturing Practice) compliance certification for the production of Rigvir virus ECHO-7.
Read More
The Advent of Oncolytic Virotherapy in Oncology:
The Rigvir® Story
Numerous viruses have been tested in clinical trials and three are approved. Our virus was the first.
Full Publication
Pioneers of Oncolytic Virotherapy with Biotechnological Focus
We are committed to prove, that the cancer treatment can be safe, effective and harmless.
Our Company
We are Excited About the Future and Proud of Our Past
In the 1960s with the efforts of professor Aina Muceniece the focus points in the perception of cancer started to shift.
Our HistoryWatch Video
From Virotherapy Focus to Vision of Life Science
Innovations in biotechnological cancer treatments are the key concepts for improving the health quality of global population.
Focus Areas